GSK’s Shingrix Gets Positive CHMP Opinion For Prevention Of Shingles

GlaxoSmithKline plc (GSK,GSK.L) said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has issued a positive opinion recommending marketing authorisation for Shingrix (RELATED: CDC backs GSK’s Shingrix over Merck & Co’s Zostavax) for the prevention of shingles, or herpes zoster, and post-herpetic neuralgia or PHN

• Source: rttnews
• 610
• January 30, 2018